Abstract
Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), has often been implicated in prostate cancer. Studies in prostate tumor cell lines revealed that Akt activation is probably important for the progression of prostate cancer to an androgen-independent state. Investigations of human prostate cancer tissues show that although there is neither Akt gene amplification nor enhanced protein expression in prostate cancer compared to normal tissue, poorly differentiated tumors exhibit increased expression of a phosphorylated (activated) form of Akt compared to normal tissue, prostatic intraepithelial neoplasia (PIN) or well-differentiated prostate cancer. Akt phosphorylation is accompanied by the inactivation of ERK, a member of the mitogen activated protein kinase (MAPK) family. In this article, we postulate that Akt promotes androgen-independent survival of prostate tumor cells by modulating the expression and activation of the androgen receptor (AR).
Keywords: akt, pi3k, androgen receptor, mapk, pten, prostate cancer
Current Drug Metabolism
Title: Akt in Prostate Cancer: Possible Role in Androgen-Independence
Volume: 4 Issue: 6
Author(s): Paramita M. Ghosh, Shazli Malik, Roble Bedolla and Jeffrey I. Kreisberg
Affiliation:
Keywords: akt, pi3k, androgen receptor, mapk, pten, prostate cancer
Abstract: Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), has often been implicated in prostate cancer. Studies in prostate tumor cell lines revealed that Akt activation is probably important for the progression of prostate cancer to an androgen-independent state. Investigations of human prostate cancer tissues show that although there is neither Akt gene amplification nor enhanced protein expression in prostate cancer compared to normal tissue, poorly differentiated tumors exhibit increased expression of a phosphorylated (activated) form of Akt compared to normal tissue, prostatic intraepithelial neoplasia (PIN) or well-differentiated prostate cancer. Akt phosphorylation is accompanied by the inactivation of ERK, a member of the mitogen activated protein kinase (MAPK) family. In this article, we postulate that Akt promotes androgen-independent survival of prostate tumor cells by modulating the expression and activation of the androgen receptor (AR).
Export Options
About this article
Cite this article as:
Ghosh M. Paramita, Malik Shazli, Bedolla Roble and Kreisberg I. Jeffrey, Akt in Prostate Cancer: Possible Role in Androgen-Independence, Current Drug Metabolism 2003; 4 (6) . https://dx.doi.org/10.2174/1389200033489226
DOI https://dx.doi.org/10.2174/1389200033489226 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Progress in Topical siRNA Delivery Approaches for Skin Disorders
Current Pharmaceutical Design 2-(2-Arylidenehydrazinyl) Thiazol-4(5H)-ones as Epidermal Growth Factor Receptor Inhibitors: A Combined Quantitative Structure Activity Relationship and Pharmacophore Study
Current Enzyme Inhibition Meet the Editorial Board:
Current Medicinal Chemistry Editorial [ Are Peptide Therapeutics the Future? Guest Editor: Sivaram Pillarisetti ]
Current Pharmaceutical Biotechnology Importance of P-gp PET Imaging in Pharmacology
Current Pharmaceutical Design Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Cytochrome P450 Retinoic Acid 4-Hydroxylase Inhibitors: Potential Agents for Cancer Therapy
Mini-Reviews in Medicinal Chemistry Role of Liprins in the Regulation of Tumor Cell Motility and Invasion
Current Cancer Drug Targets Epstein-Barr Virus-associated Gastric Cancer and Potential Mechanisms of Oncogenesis
Current Cancer Drug Targets Role of Epithelial Mesenchymal Transition in Prostate Tumorigenesis
Current Pharmaceutical Design Neurotensin NTS1-Dopamine D2 Receptor-Receptor Interactions in Putative Receptor Heteromers: Relevance for Parkinson`s Disease and Schizophrenia
Current Protein & Peptide Science Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress
Reviews on Recent Clinical Trials Glyoxalase Pathway of Trypanosomatid Parasites: A Promising Chemotherapeutic Target
Current Drug Targets Pleiotropic Effects of Omega-3 Fatty Acids
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Current Cancer Drug Targets Advances in Transient Receptor Potential Vanilloid-2 Channel Expression and Function in Tumor Growth and Progression
Current Protein & Peptide Science The Dilemma of Localizing Disease Relapse After Radical Treatment for Prostate Cancer: Which is the Value of the Actual Imaging Techniques?
Current Radiopharmaceuticals Cytostatic Effect of the Nucleoside Analogue 2-Chloroadenosine on Human Prostate Cancer Cell Line
Current Pharmaceutical Analysis Downstream Carcinogenesis Signaling Pathways by Green Tea Polyphenols: A Translational Perspective of Chemoprevention and Treatment for Cancers
Current Drug Metabolism Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma
Current Pharmaceutical Biotechnology